^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CALR (Calreticulin)

    i
    Other names: CALR, Calreticulin, Sicca Syndrome Antigen A (Autoantigen Ro; Calreticulin), Endoplasmic Reticulum Resident Protein 60, Calregulin, CC1qR, CRP55, ERp60, HACBP, Grp60, CRT, SSA, RO, Epididymis Secretory Sperm Binding Protein Li 99n, Autoantigen Ro, HEL-S-99n, FLJ26680, CRTC
    3d
    Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis. (PubMed, Int J Hematol)
    Use of ruxolitinib was reported in 14% of PV and 34% of fibrotic PMF patients, with no serious adverse events. This study represents the first large-scale prospective MPN registry in Japan. Ongoing follow-up will provide critical insights into long-term outcomes and therapeutic optimization in the Japanese population.
    Observational data • Journal • JAK2V617F
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib)
    4d
    Construct Optimization Enables Oncolytic Virus-Mediated Functional Membrane Localization of Calreticulin and Macrophage Reprogramming. (PubMed, Hum Gene Ther)
    In vivo, oAd-CMV-CALR suppresses Hepa1-6 xenograft growth, boosts CD8+ T-cell infiltration, and exhibits favorable safety. Collectively, our findings highlight oAd-CMV-CALR as a potential therapeutic approach to modulate the tumor microenvironment and improve cancer immunotherapy outcomes.
    Journal • IO biomarker • CALR
    |
    CD8 (cluster of differentiation 8) • CALR (Calreticulin)
    7d
    The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing. (PubMed, Front Immunol)
    The GADEKILL γδ T and NK cells were analyzed by flow cytometry for the expression of activating and inhibitory receptors and for cytotoxicity against NB, both with and without dinutuximab-β, at a 1:1 effector-to-target ratio...Finally, NB cell lysis positively correlated with B7H6 and BTN2A1, and B7H6-blocking experiments revealed a significant decrease in target cell lysis when cells highly expressing B7H6 were used as targets. Our study demonstrated the potential antineuroblastoma activity of the GADEKILL, supporting its therapeutic use, particularly in the context of relapsed/refractory R/R HR-NB with low GD2 expression.
    Journal • IO biomarker
    |
    LAMP1 (Lysosomal Associated Membrane Protein 1) • BTN2A1 (Butyrophilin Subfamily 2 Member A1) • CALR (Calreticulin) • BTN3A1 (Butyrophilin Subfamily 3 Member A1) • NKG2D (killer cell lectin like receptor K1)
    |
    Unituxin (dinutuximab)
    8d
    Electrochemical biosensors for Calreticulin in lung Cancer. (PubMed, Clin Chim Acta)
    In the future, it is possible to add microfluidic multiplexing platforms to perform multi-biomarker analysis simultaneously, develop point-of-care devices based on artificial intelligence-assisted data interpretation, and conduct clinical validation programs that determine diagnostic reference intervals in various patient groups. Such technological improvements will most likely support the early detection of cancer, better risk stratification of patients, and refinement of clinical laboratory workflows for accurate oncology practice.
    Review • Journal • CALR
    |
    CALR (Calreticulin)
    8d
    Mechanisms of cerebral venous sinus thrombosis due to essential thrombocythemia: Current status and future perspectives. (PubMed, Thromb Res)
    Diagnostically, MRI/MRV is the first choice, with the primary challenge being the differentiation of venous sinus hypoplasia from thrombosis in ET patients, combined with the detection of the JAK2 mutation for confirmation. This review summarizes the genetic and cellular mechanisms linking ET to CVST, discusses tailored diagnostic strategies and therapies (JAK inhibitors, anticoagulants), and highlights the need for further research to clarify the interplay between molecular abnormalities and vascular factors, aiming to optimize clinical management.
    Review • Journal • JAK2V617F
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin)
    |
    CALR mutation
    10d
    Transcriptome and single-cell RNA sequencing analysis with 101 machine learning combinations and experimental verification reveals the mechanism of action of mannose metabolism in bladder cancer. (PubMed, Front Immunol)
    Four mannose metabolism-related prognostic genes were identified in BLCA, and macrophages were confirmed as critical cells. These findings provide valuable insights for improving prognostic assessment in BLCA.
    Journal
    |
    CALR (Calreticulin) • PFKFB4 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4)
    10d
    Calreticulin-Mediated Quality Control of the Non-Classical MHC-I Molecule MICA: Implications for Immune Surveillance. (PubMed, Int J Mol Sci)
    Recombinant protein assays and in silico analyses support direct interaction between CRT and non-glycosylated MICA, but not with fully glycosylated eukaryotic MICA. These findings identify CRT-dependent retention of MICA as a physiological checkpoint that may be dysregulated in melanoma to promote immune evasion.
    Journal • CALR
    |
    CALR (Calreticulin) • MICA (MHC Class I Polypeptide-Related Sequence A)
    11d
    Photodynamic priming with Vitamin D and ALA-based PDT induces intratumoral immune cell recruitment and signaling pathway activation in murine cutaneous squamous cell carcinoma. (PubMed, bioRxiv)
    Collectively, these findings demonstrate that VitD reprograms the immune response to PDT by enhancing cytotoxic immunity while limiting immunosuppressive features. This suggests an immune-priming strategy to consider, possibly alongside immune checkpoint blockade, for treating cutaneous SCC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD69 (CD69 Molecule) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    11d
    Induction of immunogenic cell death by active components of natural products reshaping the tumor microenvironment for enhanced antitumor immunity. (PubMed, Front Pharmacol)
    Inducing ICD with NPs is a viable therapeutic strategy to potentiate anti-tumor immunity. The convergence of NPs-based ICD inducers with nanotechnology-based delivery systems offers a robust platform for the development of innovative combination regimens aimed at improving patient outcomes.
    Review • Journal • IO biomarker
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    11d
    Single-cell analysis reveals the prognostic role of immune escape in the colorectal cancer microenvironment. (PubMed, Transl Cancer Res)
    In contrast, HEXIM1+CAF-C1 may act as an independent risk factor for poor prognosis in CRC. Our findings enhance understanding of immune escape mechanisms in CRC, show how novel subtypes affect prognosis, and offer insights for new diagnostic and treatment strategies.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1) • TGFB1 (Transforming Growth Factor Beta 1) • CALR (Calreticulin) • CFLAR (CASP8 and FADD-like apoptosis regulator) • HEXIM1 (HEXIM P-TEFb Complex Subunit 1) • TAP1 (Transporter 1)
    13d
    The Role and Impact of Non-driver Gene Mutations in Myelofibrosis. (PubMed, Curr Hematol Malig Rep)
    This review offers an updated synthesis of the evolving molecular landscape of MF, highlighting how the intricate interplay among genetic alterations has deepened our understanding of disease heterogeneity, allowing refined risk stratification and therapeutic planning. Advances emerging from molecular research and experimental models are progressively translating into clinical practice, promoting more personalized and targeted approaches to the management of MF.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    14d
    Phytol Suppresses Androgen Receptor Nuclear Localization and Doubles Survival in Nude Mice Bearing Castration-Resistant Prostate Cancer Xenografts. (PubMed, Phytother Res)
    Pharmacokinetic and pharmacodynamic analyses further supported TaxO's favorable safety profile. These findings highlight TaxO as a promising plant-based therapeutic candidate for targeting AR-driven prostate cancer, warranting further clinical investigation.
    Preclinical • Journal
    |
    AR (Androgen receptor) • CALR (Calreticulin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    AR positive